New Treatments Improve Hepatocellular Carcinoma Survival
Research reported in the latest Clinical Gastroenterology & Hepatology
suggests that the therapeutic interventions for hepatocellular carcinoma
Hepatocellular carcinoma is one of the most common cancers worldwide.
Therapeutic approaches for hepatocellular carcinoma have progressed rapidly.
However, it remains unknown whether the current management of patients with
hepatocellular carcinoma has reduced its mortality.
Dr Naota Taura and colleagues from Japan analyzed changes of survival rate
in patients with hepatocellular carcinoma over a 20-year period.
Surgical resection had a better prognosis during the latter than the early
period -- Clinical Gastroenterology & Hepatology
Between 1982 and 2001, 463 patients were diagnosed with hepatocellular at
the team's hospital.
The team enrolled 257 subjects in this cohort according to inclusion
criteria, and were categorized into 5-year intervals
The patients had hepatocellular carcinoma lesion measuring less than 3 cm in
diameter, no evidence of extrahepatic metastasis, and no evidence of main
portal vein infiltration/thrombosis.
The researchers found survival rates improved significantly during the study
When the patients were stratified according to Child-Pugh score, only
patients with Child's B showed improved survival rates.
Furthermore, the team noted that patients with surgical resection or
transarterial chemoembolization during the latter period had a better
prognosis than during the early period.
Dr Taura's team concludes, “Our findings suggest that the development of
therapeutic interventions for hepatocellular carcinoma have led to
improvements in the prognosis for hepatocellular carcinoma patients.”
Clin Gastroenterol Hepatol 2006: 4(9): 1177-83